Background: The coronavirus disease 2019 (COVID-19) pandemic has challenged the ability to do face-to-face training on advanced diabetes management technologies. In the United States, Medtronic Diabetes shifted from occasional to 100% virtual training on all diabetes devices in mid-March 2020. We studied the outcomes of virtual training on the MiniMed™ 670 G hybrid closed-loop system in type 1 diabetes. Methods: From March 20, 2020, to April 22, 2020 (intra-COVID-19), virtual training on the MiniMed 670 G system was completed using Zoom with satisfaction captured through online post-training surveys. Training efficiency was measuring by the days between the date of product shipment and the date of the first and final trainings. Patient satisfaction with training on the MiniMed 670 G was determined by Net Promotor Score® (NPS®). Uploads from CareLink™ Personal and CareLink Professional and calls to the Medtronic 24-h technical support team requesting educational/software assistance and/or help with health care provider telehealth visits were recorded. Continuous glucose monitoring (CGM) results were measured using the CareLink Personal database. All results except for the Zoom satisfaction survey were compared with data from January 20, 2020, to February 22, 2020, (Pre-COVID-19) when training was performed in-person. Results: The CGM metrics were comparable between pre- and intra-COVID-19 training. The Zoom video conferencing application had 98% satisfaction. The NPS rose from 78 to 84. The time between the pump shipment and the first and last (automode) training was significantly reduced from 14 ± 7 days to 11 ± 5 days (P < 0.001) and from 19 ± 7 days to 15 ± 15 days (P < 0.01), respectively. There was a decrease in the calls for educational assistance to the technical support team but an increase in requests for login and software installation support. Conclusions: Virtual training of individuals with diabetes on the MiniMed 670 G system resulted in high satisfaction and short-term glycemic results comparable with in-person training.
Background: The coronavirus disease 2019 (COVID-19) pandemic has challenged the ability to do face-to-face training on advanced diabetes management technologies. In the United States, Medtronic Diabetes shifted from occasional to 100% virtual training on all diabetes devices in mid-March 2020. We studied the outcomes of virtual training on the MiniMed™ 670 G hybrid closed-loop system in type 1 diabetes. Methods: From March 20, 2020, to April 22, 2020 (intra-COVID-19), virtual training on the MiniMed 670 G system was completed using Zoom with satisfaction captured through online post-training surveys. Training efficiency was measuring by the days between the date of product shipment and the date of the first and final trainings. Patient satisfaction with training on the MiniMed 670 G was determined by Net Promotor Score® (NPS®). Uploads from CareLink™ Personal and CareLink Professional and calls to the Medtronic 24-h technical support team requesting educational/software assistance and/or help with health care provider telehealth visits were recorded. Continuous glucose monitoring (CGM) results were measured using the CareLink Personal database. All results except for the Zoom satisfaction survey were compared with data from January 20, 2020, to February 22, 2020, (Pre-COVID-19) when training was performed in-person. Results: The CGM metrics were comparable between pre- and intra-COVID-19 training. The Zoom video conferencing application had 98% satisfaction. The NPS rose from 78 to 84. The time between the pump shipment and the first and last (automode) training was significantly reduced from 14 ± 7 days to 11 ± 5 days (P < 0.001) and from 19 ± 7 days to 15 ± 15 days (P < 0.01), respectively. There was a decrease in the calls for educational assistance to the technical support team but an increase in requests for login and software installation support. Conclusions: Virtual training of individuals with diabetes on the MiniMed 670 G system resulted in high satisfaction and short-term glycemic results comparable with in-person training.
Authors: Faisal S Malik; Katherine A Sauder; Scott Isom; Beth A Reboussin; Dana Dabelea; Jean M Lawrence; Alissa Roberts; Elizabeth J Mayer-Davis; Santica Marcovina; Lawrence Dolan; Daria Igudesman; Catherine Pihoker; Jean M Lawrence; Peggy Hung; Corinna Koebnick; Xia Li; Eva Lustigova; Kristi Reynolds; David J Pettitt; Elizabeth J Mayer-Davis; Amy Mottl; Joan Thomas; Malaka Jackson; Lisa Knight; Angela D Liese; Christine Turley; Deborah Bowlby; James Amrhein; Elaine Apperson; Bryce Nelson; Dana Dabelea; Anna Bellatorre; Tessa Crume; Richard F Hamman; Katherine A Sauder; Allison Shapiro; Lisa Testaverde; Georgeanna J Klingensmith; David Maahs; Marian J Rewers; Paul Wadwa; Stephen Daniels; Michael G Kahn; Greta Wilkening; Clifford A Bloch; Jeffrey Powell; Kathy Love-Osborne; Diana C Hu; Lawrence M Dolan; Amy S Shah; Debra A Standiford; Elaine M Urbina; Catherine Pihoker; Irl Hirsch; Grace Kim; Faisal A Malik; Lina Merjaneh; Alissa Roberts; Craig Taplin; Joyce Yi-Frazier; Natalie Beauregard; Cordelia Franklin; Carlo Gangan; Sue Kearns; Mary Klingsheim; Beth Loots; Michael Pascual; Carla Greenbaum; Giuseppina Imperatore; Sharon H Saydah; Barbara Linder; Santica M Marcovina; Alan Chait; Noemie Clouet-Foraison; Jessica Harting; Greg Strylewicz; Ralph D'Agostino; Elizabeth T Jensen; Lynne E Wagenknecht; Ronny A Bell; Ramon Casanova; Jasmin Divers; Maureen T Goldstein; Leora Henkin; Scott Isom; Kristin Lenoir; June Pierce; Beth Reboussin; Joseph Rigdon; Andrew Michael South; Jeanette Stafford; Cynthia Suerken; Brian Wells; Carrie Williams Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Erin C Cobry; Tyler Reznick-Lipina; Laura Pyle; Robert Slover; John F Thomas; Guy Todd Alonso; Raj Paul Wadwa Journal: Diabetes Technol Ther Date: 2022-01 Impact factor: 6.118
Authors: A Sathyanarayanan; T Crabtree; P Choudhary; J Elliott; M L Evans; A Lumb; E G Wilmot Journal: Diabetes Res Clin Pract Date: 2022-02-11 Impact factor: 8.180
Authors: Jennifer L Sherr; Lutz Heinemann; G Alexander Fleming; Richard M Bergenstal; Daniela Bruttomesso; Hélène Hanaire; Reinhard W Holl; John R Petrie; Anne L Peters; Mark Evans Journal: Diabetologia Date: 2022-10-06 Impact factor: 10.460